Young Pampee P, Vaughan Douglas E, Hatzopoulos Antonis K
Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Prog Cardiovasc Dis. 2007 May-Jun;49(6):421-9. doi: 10.1016/j.pcad.2007.02.004.
Recent studies indicate that portions of ischemic and tumor neovasculature are derived by neovasculogenesis, whereby bone marrow (BM)-derived circulating endothelial progenitor cells (EPCs) home to sites of regenerative or malignant growth and contribute to blood vessel formation. Recent data from animal models suggest that a variety of cell types, including unfractionated BM mononuclear cells and those obtained by ex vivo expansion of human peripheral blood or enriched progenitors, can function as EPCs to promote tissue vasculogenesis, regeneration, and repair when introduced in vivo. The promising preclinical results have led to several human clinical trials using BM as a potential source of EPCs in cardiac repair as well as ongoing basic research on using EPCs in tissue engineering or as cell therapy to target tumor growth.
最近的研究表明，缺血性和肿瘤新生血管的一部分是通过新生血管形成产生的，即骨髓来源的循环内皮祖细胞归巢到再生或恶性生长部位，并参与血管形成。动物模型的最新数据表明，多种细胞类型，包括未分离的骨髓单个核细胞以及通过体外扩增人外周血或富集祖细胞获得的细胞，在体内引入时可作为内皮祖细胞发挥作用，促进组织血管生成、再生和修复。这些有前景的临床前结果已促成了多项人体临床试验，将骨髓作为心脏修复中内皮祖细胞的潜在来源，同时也有正在进行的关于在组织工程中使用内皮祖细胞或作为靶向肿瘤生长的细胞疗法的基础研究。
